Eagle Pharmaceuticals Inc. (EGRX)

59.49
NASDAQ : Health Technology
Prev Close 59.49
Day Low/High 0.00 / 0.00
52 Wk Low/High 49.14 / 85.66
Avg Volume 220.30K
Exchange NASDAQ
Shares Outstanding 14.86M
Market Cap 907.03M
EPS 3.40
P/E Ratio 31.95
Div & Yield N.A. (N.A)

Latest News

Eagle Pharmaceuticals, Inc. To Present At Cantor Global Healthcare Conference

Eagle Pharmaceuticals, Inc. To Present At Cantor Global Healthcare Conference

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ: EGRX) announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the Cantor Global Healthcare Conference as follows:            ...

(Photo: Business Wire)

(Photo: Business Wire)

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or "the Company") today announced that the Compensation Committee of the Company's Board of Directors has approved the appointment of David Pernock to the position of Chief Operating Officer, effective...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: INT, RLJ Downgrades: AN, EGRX, WTTR Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Eagle Pharmaceuticals, Inc. To Present At Morgan Stanley 16th Annual Global Healthcare Conference

Eagle Pharmaceuticals, Inc. To Present At Morgan Stanley 16th Annual Global Healthcare Conference

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ: EGRX) announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the Morgan Stanley 16 th Annual Global Healthcare Conference as...

Eagle Pharmaceuticals Concludes Enrollment Of Second Safety And Efficacy Study At Hajj To Evaluate RYANODEX For Exertional Heat Stroke

Eagle Pharmaceuticals Concludes Enrollment Of Second Safety And Efficacy Study At Hajj To Evaluate RYANODEX For Exertional Heat Stroke

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq:EGRX) today announced completion of enrollment of the Company's second clinical study to further evaluate the safety and efficacy of RYANODEX® (dantrolene sodium for injectable suspension) for...

Eagle Pharmaceuticals Named To Fortune 100 List Of Fastest-Growing Companies

Eagle Pharmaceuticals Named To Fortune 100 List Of Fastest-Growing Companies

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or "the Company") today announced that the Company has been named to the Fortune 100 List of Fastest-Growing Companies, ranking 16 th overall, including achieving the #1 positions for EPS 3-year growth of...

Eagle Pharmaceuticals Announces New Patent Issued For BENDEKA

Eagle Pharmaceuticals Announces New Patent Issued For BENDEKA

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or "the Company") today announced that an additional patent has been issued related to BENDEKA ® by the United States Patent and Trademark Office (USPTO).

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AVT, CROX, CYBR, EGRX, GWRS, HSTM, LITE, NRP, NTRA, OSUR, SITE, USM Downgrades: AAXN, BDGE, BPFH, MCHP, ORA, QEP, SJI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Eagle Pharmaceuticals, Inc. Reports Second Quarter 2018 Results

Eagle Pharmaceuticals, Inc. Reports Second Quarter 2018 Results

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq:EGRX) today announced its financial results for the three and six months ended June 30, 2018.

EGRX Crosses Above Average Analyst Target

EGRX Crosses Above Average Analyst Target

In recent trading, shares of Eagle Pharmaceuticals, Inc. have crossed above the average analyst 12-month target price of $76.00, changing hands for $77.70/share.

Eagle Pharmaceuticals, Inc. To Discuss Second Quarter 2018 Financial Results On August 7, 2018

Eagle Pharmaceuticals, Inc. To Discuss Second Quarter 2018 Financial Results On August 7, 2018

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq: EGRX) today announced that the Company will release its 2018 second quarter financial results on Tuesday, August 7, 2018, before the market opens.

FDA Grants Eagle Seven Year Orphan Drug Exclusivity For BENDEKA (bendamustine Hydrochloride Injection)

FDA Grants Eagle Seven Year Orphan Drug Exclusivity For BENDEKA (bendamustine Hydrochloride Injection)

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") announced today that the U.

Eagle Pharmaceuticals Announces New Patent Issued For BENDEKA

Eagle Pharmaceuticals Announces New Patent Issued For BENDEKA

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or "the Company") today announced that an additional patent has been issued related to BENDEKA ® by the United States Patent and Trademark Office (USPTO).

Court Issues Decision In Favor Of Eagle Pharmaceuticals Granting Seven Year Orphan Drug Exclusivity For BENDEKA (bendamustine Hydrochloride Injection)

Court Issues Decision In Favor Of Eagle Pharmaceuticals Granting Seven Year Orphan Drug Exclusivity For BENDEKA (bendamustine Hydrochloride Injection)

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or the "Company") announced today that the U.

Eagle Pharmaceuticals, Inc. Granted Final FDA Approval For Bendamustine Hydrochloride Ready-to-Dilute Solution In A 500ml Admixture

Eagle Pharmaceuticals, Inc. Granted Final FDA Approval For Bendamustine Hydrochloride Ready-to-Dilute Solution In A 500ml Admixture

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq:EGRX) today announced that the U.

EGRX Crosses Above Average Analyst Target

In recent trading, shares of Eagle Pharmaceuticals, Inc. have crossed above the average analyst 12-month target price of $64.33, changing hands for $65.57/share.

Eagle Pharmaceuticals, Inc. Reports First Quarter 2018 Results

Eagle Pharmaceuticals, Inc. Reports First Quarter 2018 Results

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq: EGRX) today announced its financial results for the three months ended March 31, 2018.

EGRX Crosses Above Key Moving Average Level

In trading on Monday, shares of Eagle Pharmaceuticals, Inc. crossed above their 200 day moving average of $56.30, changing hands as high as $58.25 per share.

Eagle Pharmaceuticals, Inc. To Discuss First Quarter 2018 Financial Results On May 10, 2018

Eagle Pharmaceuticals, Inc. To Discuss First Quarter 2018 Financial Results On May 10, 2018

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq: EGRX) today announced that the Company will release its 2018 first quarter financial results on Thursday, May 10, 2018, before the market opens.

Eagle Pharmaceuticals, Inc. To Present At 43rd Annual Deutsche Bank Health Care Conference

Eagle Pharmaceuticals, Inc. To Present At 43rd Annual Deutsche Bank Health Care Conference

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 43rd Annual Deutsche Bank Health Care Conference as follows:   ...

Three Biotech Names to Consider

Three Biotech Names to Consider

A look at three names to consider in the biotech and biopharma space.

Eagle Pharmaceuticals Announces New Patent For Eagle Biologics

Eagle Pharmaceuticals Announces New Patent For Eagle Biologics

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or "the Company") today announced that the Company's Eagle Biologics division has been issued a new patent by the United States Patent and Trademark Office (USPTO).

Eagle Pharmaceuticals, Inc. Reports Fourth Quarter And Full Year 2017 Results

Eagle Pharmaceuticals, Inc. Reports Fourth Quarter And Full Year 2017 Results

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq: EGRX) today announced its financial results for the three- and twelve-months ended December 31, 2017.

Eagle Pharmaceuticals, Inc. To Discuss Fourth Quarter And Year End 2017 Financial Results On February 26, 2018

Eagle Pharmaceuticals, Inc. To Discuss Fourth Quarter And Year End 2017 Financial Results On February 26, 2018

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq: EGRX) today announced that the Company will release its 2017 fourth quarter and full year financial results on Monday, February 26, 2018, before the market...

EGRX Crosses Above Key Moving Average Level

EGRX Crosses Above Key Moving Average Level

In trading on Thursday, shares of Eagle Pharmaceuticals, Inc. crossed above their 200 day moving average of $62.84, changing hands as high as $63.52 per share.

Eagle Pharmaceuticals, Inc. To Present At 2018 RBC Capital Markets Global Healthcare Conference

Eagle Pharmaceuticals, Inc. To Present At 2018 RBC Capital Markets Global Healthcare Conference

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or "the Company") today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 2018 RBC Capital Markets Global...

Eagle Pharmaceuticals Announces Fifth Orange Book Listed Patent For RYANODEX

Eagle Pharmaceuticals Announces Fifth Orange Book Listed Patent For RYANODEX

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or "the Company") today announced that the Company has been issued a new patent related to its RYANODEX ® product (dantrolene sodium for injectable suspension) by the...

TheStreet Quant Rating: C+ (Hold)